What lies beneath the surface? Ultrasound is revealing the earliest signs of psoriatic arthritis, and changing care in the ...

TREMFYA® (guselkumab) is now clinically proven to protect joints in active psoriatic arthritis, offering durable efficacy and ...

Discover how early biologic therapy compares with standard care in psoriatic arthritis. Learn more about treatment strategies ...

Johnson & Johnson (J&J) has announced new data showing that Tremfya (guselkumab) reduces symptoms of psoriatic arthritis (PsA ...

Joint pain, fatigue, and flares that strike without warning can make life with psoriatic arthritis challenging. Here's a ...

Advancements in drug development, rising disease awareness, and enhanced diagnostics are driving the psoriatic arthritis treatment market. Key opportunities lie in biologic and targeted therapies, ...

In the video, Dr. Nicola J. Gullick, a Consultant Rheumatologist in Coventry and one of the investigators on the PRO-SPIRIT ...

New 48-week data from the Phase IIIb APEX trial (NCT04882098) show Tremfya (guselkumab; Johnson & Johnson) produces sustained inhibition of radiographic progression and improved clinical symptoms in ...

Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit ...

GREEN BAY, Wis., Nov. 28, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Donald Massenburg, MD, Ph.D, FACP, FACR is recognized as a Pinnacle Lifetime Member for his contributions to ...

Tremfya demonstrated sustained reduction in PsA symptoms and inhibited structural damage progression at 48 weeks in the APEX trial. Patients switching from placebo to Tremfya experienced a 57% ...

Bengaluru: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval ...